Guggenheim on Celldex Therapeutics (CLDX): 'We continue to think today's stock reaction is overdone'

Leerink Partners Reiterates Outperform Rating on Celldex Therapeutics (CLDX)

September 26, 2024 7:24 AM EDT

Leerink Partners analyst Thomas Smith reiterated an Outperform rating and $78.00 price target on Celldex Therapeutics (NASDAQ: CLDX).

The analyst comments "Bottom Line: CLDX (OP) presented highly anticipated 52-week data from a Phase 2 study of barzolvolimab (barzo; anti-KIT antibody) in chronic spontaneous urticaria... More

H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)

September 26, 2024 6:28 AM EDT

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $80.00 price target on Celldex Therapeutics (NASDAQ: CLDX).

The analyst comments "Barzo's durability is showcased at EADV '24 in a later breaking oral presentation. In an oral presentation at EADV '24, Celldex announced new data,... More

Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Overweight

September 25, 2024 3:47 PM EDT

Wells Fargo analyst Derek Archila upgraded Celldex Therapeutics (NASDAQ: CLDX) from Equal Weight to Overweight with a price target of $44.00.

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $40.96 yesterday.

... More

Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)

September 25, 2024 2:33 PM EDT

Stifel analyst Alex Thompson reiterated a Buy rating and $58.00 price target on Celldex Therapeutics (NASDAQ: CLDX).

The analyst commented, "CLDX presented full trial results from the 52-week Ph2 CSU study today at EADV achieving sustained/improved reductions on UAS7 across all... More

Celldex (CLDX) Halted on Volatility, Down 21% Following 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

September 25, 2024 11:02 AM EDT

Celldex (NASDAQ: CLDX) Halted on Volatility, Down 21%

- 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across... More

Celldex (CLDX) Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

September 25, 2024 10:45 AM EDT

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data are bring presented today by Dr. Martin Metz, Professor of Dermatology and Allergy at Charité -... More